A Safety and Efficacy Study of Tavilermide Ophthalmic Solution for the Treatment of Dry Eye
Phase of Trial: Phase III
Latest Information Update: 29 Mar 2017
At a glance
- Drugs Tavilermide (Primary)
- Indications Keratoconjunctivitis sicca
- Focus Therapeutic Use
- Sponsors Mimetogen Pharmaceuticals
- 24 Mar 2017 Status changed from active, no longer recruiting to completed.
- 12 Sep 2016 Planned End Date changed from 1 Jul 2016 to 1 Sep 2016.
- 12 Sep 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Sep 2016.